Literature DB >> 8655709

Diagnostic difficulty arising from rectal recovery in ulcerative colitis.

T S Levine1, M Tzardi, S Mitchell, C Sowter, A B Price.   

Abstract

AIMS: To ascertain whether the dogma that a normal rectal biopsy precludes a diagnosis of ulcerative colitis is correct.
METHODS: Rectal biopsy specimens from a prospective group of 24 asymptomatic patients, with an established diagnosis of ulcerative colitis, were examined in a blinded study alongside 10 normal rectal biopsy specimens from an age and sex matched patient cohort without ulcerative colitis. Each biopsy specimen was assessed by three pathologists and ascribed to one of four categories: normal; borderline abnormality (one or more minor nonspecific abnormalities which, when combined, did not fulfil the minimal acceptable criteria for a diagnosis of ulcerative colitis); minimal features of chronic ulcerative colitis; and unequivocal ulcerative colitis.
RESULTS: Two patients with ulcerative colitis had normal biopsy specimens; nine specimens were categorised as borderline abnormality, one as showing the minimal changes of chronic ulcerative colitis, and 12 as having the typical changes of chronic ulcerative colitis. Thus, 11 (46%) of the 24 patients had a rectal biopsy specimen that was devoid of the acceptable attributes on which a diagnosis is established, despite a confident previous diagnosis. Ten of these 11 cases had disease limited to the rectum. Review of all previous histological biopsy specimens (n = 164) and clinical data, including drug treatment, failed to identify any attributes that might be prognostic markers for future rectal mucosal healing.
CONCLUSIONS: A normal rectal biopsy specimen, though uncommon, may occur in longstanding colitis. Moreover, in 46% of these asymptomatic but established cases the degree of healing may preclude a diagnosis of ulcerative colitis without comprehensive clinical and radiological details. Pathologists need to be aware of this minimal end of the spectrum of disease.

Entities:  

Mesh:

Year:  1996        PMID: 8655709      PMCID: PMC500459          DOI: 10.1136/jcp.49.4.319

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Morphometric studies in rectal biopsy specimens from patients with ulcerative colitis: effect of oral 5 amino salicylic acid and rectal prednisolone treatment.

Authors:  A M Zaitoun; I Cobden; H al Mardini; C O Record
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 2.  Inflammatory bowel disease (2)

Authors:  D K Podolsky
Journal:  N Engl J Med       Date:  1991-10-03       Impact factor: 91.245

Review 3.  Normal histology of the colon.

Authors:  D S Levine; R C Haggitt
Journal:  Am J Surg Pathol       Date:  1989-11       Impact factor: 6.394

Review 4.  Rectal biopsy in inflammatory bowel disease.

Authors:  B C Morson
Journal:  N Engl J Med       Date:  1972-12-28       Impact factor: 91.245

5.  Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis.

Authors:  R Odze; D Antonioli; M Peppercorn; H Goldman
Journal:  Am J Surg Pathol       Date:  1993-09       Impact factor: 6.394

  5 in total
  10 in total

Review 1.  Indeterminate colitis.

Authors:  M Guindi; R H Riddell
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

2.  Histological patchiness and sparing of the rectum in ulcerative colitis: refuting the dogma.

Authors:  C N Bernstein; F Shanahan; W M Weinstein
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

3.  Lower gastrointestinal endoscopy: guidance on indications for biopsy.

Authors:  A C Bateman; P Patel
Journal:  Frontline Gastroenterol       Date:  2013-12-20

4.  The histopathological approach to inflammatory bowel disease: a practice guide.

Authors:  Cord Langner; Fernando Magro; Ann Driessen; Arzu Ensari; Gerassimos J Mantzaris; Vincenzo Villanacci; Gabriel Becheanu; Paula Borralho Nunes; Gieri Cathomas; Walter Fries; Anne Jouret-Mourin; Claudia Mescoli; Giovanni de Petris; Carlos A Rubio; Neil A Shepherd; Michael Vieth; Rami Eliakim; Karel Geboes
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

5.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-24       Impact factor: 11.382

Review 6.  Mucosal healing and deep remission: what does it mean?

Authors:  Gerhard Rogler; Stephan Vavricka; Alain Schoepfer; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis.

Authors:  Takafumi Ando; Yuji Nishio; Osamu Watanabe; Hironao Takahashi; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

8.  Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis.

Authors:  Takafumi Ando; Hironao Takahashi; Osamu Watanabe; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Motofusa Hasegawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

9.  Histological healing after infliximab induction therapy in children with ulcerative colitis.

Authors:  Anna Wiernicka; Sylwia Szymanska; Joanna Cielecka-Kuszyk; Maciej Dadalski; Jaroslaw Kierkus
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

10.  Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  J Crohns Colitis       Date:  2020-10-05       Impact factor: 10.020

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.